Company Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States.
It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model.
The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder.
It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders.
Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 334 |
| CEO | Ronald C. Renaud Jr., M.B.A. |
Contact Details
Address: 222 Jacobs Street, Suite 200 Cambridge, Massachusetts 02141 United States | |
| Phone | 844-304-2048 |
| Website | cerevel.com |
Stock Details
| Ticker Symbol | CERE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001805387 |
| CUSIP Number | 15678U128 |
| ISIN Number | US15678U1280 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. N. Anthony Coles Jr., M.P.H. | Executive Chairman |
| Mark Bodenrader | Vice President of Finance and Chief Accounting Officer |
| Dr. John J. Renger Ph.D. | Chief Scientific Officer |
| Dr. Ramiro Sanchez M.D. | Chief Medical Officer |
| Ronald C. Renaud Jr., M.B.A. | President, Chief Executive Officer and Director |
| Dr. Susan Altschuller M.B.A., Ph.D. | Chief Financial Officer |
| Matthew Calistri | Vice President of Investor Relations |
| Scott M. Akamine J.D. | Chief Legal Officer and Corporate Secretary |
| Kenneth A. DiPietro | Chief Human Resources Officer |
| Kathleen Tregoning M.A. | Chief Corporate Affairs Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 26, 2024 | 10-K/A | [Amend] Annual report |
| Apr 1, 2024 | 144 | Filing |
| Mar 4, 2024 | 144 | Filing |
| Feb 29, 2024 | 144 | Filing |
| Feb 27, 2024 | 10-K | Annual Report |
| Feb 16, 2024 | 8-K | Current Report |
| Feb 9, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jan 18, 2024 | DEFM14A | Filing |
| Jan 18, 2024 | PRER14A | Filing |
| Jan 10, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |